14 Best Healthcare Dividend Stocks to Buy

Published on May 24, 2023 at 9:33 am by Vardah Gill in Dividend Stocks, Hedge Funds, News

In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy.

The healthcare sector in the US encompasses a wide range of providers, facilities, and services aimed at promoting and maintaining the health of the population. The industry is also a significant and crucial part of the US economy. According to the Centers for Medicare and Medicaid Services, US healthcare spending reached $4.3 trillion in 2021 and accounted for 18.3% of the national GDP. Given this growing healthcare spending, analysts have presented a positive outlook for the sector in the coming years as well. Healthcare profit pools are projected to grow at a 4% CAGR from $654 billion in 2021 to $790 billion in 2026, as reported by McKinsey & Company.

The onset of the pandemic has brought several changes and transformations in the US healthcare system. The adoption of telehealth services accelerated post-pandemic to reduce the risks of exposure. According to a report by Deloitte, 68% of physicians offered virtual health options in 2022, compared with just 14% the prior year. The report further mentioned that 57% to 80% of patients prefer telehealth services. These shifting patient preferences are likely to have a lasting impact, resulting in the further growth of the telehealth sector. Bloomberg Intelligence (BI) estimated that the sector could bring $20 billion in US revenues by 2027. The analysis also projected a 30% annual revenue growth for top telehealth providers.

Also read: 11 Best Mid-Cap Healthcare Stocks To Buy Now

The demand for healthcare-related products and services remains relatively stable despite economic conditions. This was seen in 2022 when high-interest rates caused major indices to plunge, whereas the healthcare sector maintained a solid footing and outperformed the broader market. Healthcare stocks have historically delivered stable performance during periods of economic uncertainty. In our article titled 12 Defensive Healthcare Dividend Stocks, we mentioned that these equities have outperformed in down markets from 2000 through June 2022.

In addition to their defensive nature, dividend payments from healthcare companies are appealing to investors. Dividend stocks have demonstrated their worth during previous high inflationary periods, becoming top choices for investors. Quality healthcare companies like Johnson & Johnson (NYSE:JNJ), AbbVie Inc. (NYSE:ABBV), and Merck & Co., Inc. (NYSE:MRK) have histories of strong financial performance and consistent earnings. Their ability to regularly pay and grow their dividends compels investors to pile on these stocks. In this article, we will further take a look at the best healthcare dividend stocks to buy.

Photo by Vitaly Taranov on Unsplash

Our Methodology:

For this list, we scoured Insider Monkey’s database of 943 elite funds as of Q1 2023 to determine healthcare dividend stocks that are popular among these smart money investors. Next, we shortlisted healthcare dividend companies that have raised their payouts for at least five years and also considered the respective companies’ overall financial health. We sorted these stocks by the number of hedge funds in our database with positions in these companies at the end of Q1.

14. Cardinal Health, Inc. (NYSE:CAH)

Number of Hedge Fund Holders: 50

Cardinal Health, Inc. (NYSE:CAH) is an Ohio-based multinational healthcare services company that deals in the distribution of pharmaceuticals and other medical products. The company reported strong Q1 earnings with revenue amounting to over $50.5 billion, up 13% from the same period last year. Its operating cash flow for the quarter came in at over $1.3 billion.

On May 11, Cardinal Health, Inc. (NYSE:CAH) declared a 1% hike in its quarterly dividend to $0.5006 per share. Through this increase, the company took its dividend growth streak to 37 years, which makes it one of the best dividend stocks in the healthcare sector. The stock has a dividend yield of 2.36%, as of May 23. Johnson & Johnson (NYSE:JNJ), AbbVie Inc. (NYSE:ABBV), and Merck & Co., Inc. (NYSE:MRK) are some other popular dividend stocks from the healthcare industry.

Cardinal Health, Inc. (NYSE:CAH) attracted positive Wall Street ratings after reporting earnings beat in its most recent quarter. In May, both Deutsche Bank and UBS raised their price targets on the stocks to $90 and $93, respectively.

At the end of Q1 2023, 50 hedge funds in Insider Monkey’s database owned stakes in Cardinal Health, Inc. (NYSE:CAH), the same as in the previous quarter. The collective value of these stakes is over $1.36 billion.

Ariel Investments mentioned Cardinal Health, Inc. (NYSE:CAH) in its Q3 2022 investor letter. Here is what the firm has to say:

“Additionally, distributor of pharmaceutical and medical products Cardinal Health, Inc. (NYSE:CAH) advanced in the period as leadership changes were viewed to be a positive for shares. Management provided a new profit outlook for Fiscal 2023 and announced an improvement plan for the medical segment. We are encouraged by these changes and think CAH’s underlying fundamentals and competitive advantages around preventative maintenance screenings and medication management will continue to improve. We believe valuations of health care companies like CAH that focus on cost optimization and promote technological efficiency across the supply chain will be rewarded over the long term.”

13. Medtronic plc (NYSE:MDT)

Number of Hedge Fund Holders: 52

Medtronic plc (NYSE:MDT) is an American medical device company that offers services related to medical technology. The company currently offers a quarterly dividend of $0.68 per share and has a dividend yield of 3.12%, as of May 23. It is one of the best dividend stocks on our list as it maintains a 45-year streak of consistent dividend growth.

Medtronic plc (NYSE:MDT) reported a strong cash position in its fiscal Q3 2023, which shows that the company is well-positioned to grow its dividends in the future. For nine months that ended in January 2023, the company’s operating cash flow came in at over $3.5 billion and its free cash flow amounted to $2.5 billion. Moreover, it had over $4.5 billion available in cash and cash equivalents, up from $3.7 billion during the same period last year.

Medtronic plc (NYSE:MDT) was a part of 52 hedge fund portfolios at the end of Q1 2023, as per Insider Monkey’s database. The stakes owned by these elite funds have a collective value of over $1.64 billion.

Carillon Tower Advisers mentioned Medtronic plc (NYSE:MDT) in its Q4 2022 investor letter. Here is what the firm has to say:

“Medtronic plc (NYSE:MDT) announced disappointing clinical trial results for a new product in its pipeline and lowered its fiscal 2023 financial guidance due to lingering supply chain issues and slower than expected medical procedure recovery.”

12. Becton, Dickinson and Company (NYSE:BDX)

Number of Hedge Fund Holders: 56

Becton, Dickinson and Company (NYSE:BDX) is a New Jersey-based medical technology company that mainly specializes in the production of medical devices. In May, Barclays raised its price target on the stock to $284 and kept an Overweight rating on the shares, highlighting the company’s improvements in underlying growth and execution.

On April 25, Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend of $0.91 per share, which was the same as its previous dividend. In 2022, the company hiked its dividend for the 51st consecutive year, making it one of the best dividend stocks on our list. The stock’s dividend yield on May 23 came in at 1.48%.

For the six months that ended in March 2023, Becton, Dickinson and Company (NYSE:BDX) reported an operating cash flow of $584 million. For fiscal Q2 2023, the company’s revenue came in at $4.8 billion, which showed a 1.4% growth from the same period last year.

The number of hedge funds tracked by Insider Monkey owning stakes in Becton, Dickinson and Company (NYSE:BDX) grew to 56 in Q1 2023, from 52 in the previous quarter. These stakes have a collective value of roughly $3 billion. With nearly 2 million shares, Generation Investment Management was the company’s leading stakeholder in Q1.

11. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 57

Amgen Inc. (NASDAQ:AMGN) specializes in the discovery and manufacturing of innovative human therapeutics. In the first quarter of 2023, the company generated over $0.7 billion in free cash flow. The company’s operating cash flow for the quarter came in at over $1.1 billion. It also paid over $1 billion in dividends to shareholders, which makes it one of the best dividend stocks on our list.

Amgen Inc. (NASDAQ:AMGN) offers a quarterly dividend of $2.13 per share and has a dividend yield of 3.80%, as of May 23. The company has been rewarding shareholders with growing dividends since 2011.

In May, Jefferies raised its price target on Amgen Inc. (NASDAQ:AMGN) to $325 with a Buy rating on the shares, highlighting the company’s acquisition of Horizon Therapeutics.

As of the close of Q1 2023, 57 hedge funds in Insider Monkey’s database reported having stakes in Amgen Inc. (NASDAQ:AMGN), with a collective value of over $1.68 billion. Two Sigma Advisors was the company’s largest stakeholder in Q1.

10. McKesson Corporation (NYSE:MCK)

Number of Hedge Fund Holders: 60

McKesson Corporation (NYSE:MCK) is an American healthcare company that distributes pharmaceuticals and provides related services and products to its customers. On April 27, the company declared a quarterly dividend of $0.54 per share, which was in line with its previous dividend. It has been raising its dividends consistently for the past six years.

McKesson Corporation (NYSE:MCK), one of the best dividend stocks, generated $5.2 billion in operating cash flow in its FY23. The company’s free cash for the period amounted to over $4.6 billion. Its free cash flow was sufficient to cover the shareholder obligation worth $3.9 billion. The company’s revenue amounted to over $276.7 billion for the full year, up 5% from FY22.

Following the company’s strong earnings growth and updated guidance for FY24, Credit Suisse lifted its price target on the stock to $450 in May and maintained an Outperform rating on the shares.

Medtronic plc (NYSE:MDT) was a popular buy among hedge funds in Q1 2023, as 60 elite funds in Insider Monkey’s database owned stakes in the company, up from 54 in the previous quarter. The total value of these stakes is roughly $4 billion.

Broyhill Asset Management mentioned McKesson Corporation (NYSE:MCK) in its Q4 2022 investor letter. Here is what the firm has to say:

“Shares of McKesson Corporation (NYSE:MCK) gained 50% for the twelve months ending December 2022, as opioid-related litigation concerns, which weighed on the stock for years, took a back seat to strong operating performance. When we first established the position in 2018, we explained that, “Although headlines remind us daily of growing threats to the business, the actual probability of this business dramatically changing in the next five years is much lower than the perceived probability. We are simply betting that the future might not be as bad as the price suggests.”

Consensus FY22 and FY23 EPS estimates at the time were around $17 – $18 per share. The company reported ~ $24 in earnings in FY22, and is on pace for $26 in FY23, even as consensus estimates for the broader market were repeatedly revised lower. We continued to trim our position throughout the year as shares rerated higher from ~ 8x earnings in FY18 to ~ 16x earnings at recent highs.”

9. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 60

Gilead Sciences, Inc. (NASDAQ:GILD) specializes in the research and development of antiviral drugs. In May, BMO Capital upgraded the stock to Outperform with a $100 price target, acknowledging the company’s cell therapy franchise. The firm also appreciated the company’s manufacturing capabilities and its tumor oncology business.

Gilead Sciences, Inc. (NASDAQ:GILD) offers a quarterly dividend of $0.75 per share and has a dividend yield of 3.82%, as of May 23. The company has been raising its dividends consistently for the past eight years. In the first quarter of 2023, it returned $969 million to shareholders in dividends, which makes it one of the best dividend stocks on our list.

At the end of Q1 2023, 60 hedge funds tracked by Insider Monkey owned stakes in Gilead Sciences, Inc. (NASDAQ:GILD), worth collectively nearly $4 billion.

Ariel Investments mentioned Gilead Sciences, Inc. (NASDAQ:GILD) in its Q4 2022 investor letter. Here is what the firm has to say:

“Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ:GILD. advanced in the quarter on positive data released in a study evaluating Trodelvy versus comparative chemotherapy in patients with metastatic breast cancer. The detailed findings increased investor confidence the drug would receive incremental approvals for a broader range of breast cancer treatments. Shares also received a boost on news the TAF patent portfolio for HIV drugs will be extended from the middle of this decade through the early 2030s, creating greater visibility into the company’s long-term opportunity in the virology market.”

8. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 69

Bristol-Myers Squibb Company (NYSE:BMY) is an American pharmaceutical industry company, offering innovative medical solutions to its consumers. The company is one of the best dividend stocks on our list as it maintains a 17-year streak of consistent dividend growth. It pays a quarterly dividend of $0.57 per share and has a dividend yield of 3.43%, as of May 23.

In April Credit Suisse maintained a Neutral rating on Bristol-Myers Squibb Company (NYSE:BMY) with a $72 price target, following the company’s strong Q1 earnings.

As of the close of Q1 2023, 69 hedge funds in Insider Monkey’s database reported having stakes in Bristol-Myers Squibb Company (NYSE:BMY), the same as in the previous quarter. These stakes have a consolidated value of over $1.55 billion.

7. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 72

Eli Lilly and Company (NYSE:LLY) is one of America’s oldest pharmaceutical companies. It is widely known for its drugs for clinical depression. In May, Morgan Stanley raised its price target on the stock to $507 and maintained an Overweight rating on the shares. The firm gave a positive outlook on the company’s drug trial for Alzheimer’s disease.

Eli Lilly and Company (NYSE:LLY), one of the best dividend stocks on our list, has been making dividend payments to shareholders for the past 138 years. Moreover, the company holds a 9-year streak of growing its dividends consistently. It currently pays a quarterly dividend of $1.13 per share for a dividend yield of 1.07%, as of May 23.

As per Insider Monkey’s Q1 2023 database, 72 hedge funds owned stakes in Eli Lilly and Company (NYSE:LLY), down from 76 in the preceding quarter. These stakes are collectively valued at over $3.7 billion.

Fred Alger Management mentioned Eli Lilly and Company (NYSE:LLY) in its Q1 2023 investor letter. Here is what the firm has to say:

“Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company with core franchises in diabetes, obesity, neurology, and oncology. The company offered exposure to therapeutics in obesity and diabetes via the launch of Mounjaro, as well as in Alzheimer’s via Donanemab which was filed in November 2022 for accelerated Phase 3 approval in mid-2023. While the company reported decent fiscal fourth quarter results, shares detracted from performance after a modest miss in their obesity and diabetes drug. Mounjaro. Moreover, investors became skeptical of potential regulatory scrutiny around Donanemab and its efficacy relative to Biogen’s competing offering.”

6. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 73

Pfizer Inc. (NYSE:PFE) is an American multinational biotech and pharmaceutical company. In May, Barclays maintained a Neutral rating on the stock with a $40 price target after the company announced its Q1 earnings. The firm expressed concerns about the company’s performance due to its new launches this year.

Pfizer Inc. (NYSE:PFE), one of the best dividend stocks, currently pays a quarterly dividend of $0.41 per share and has a dividend yield of 4.14%, as of May 23. The company has raised its dividends for 13 years running. It can be a reliable investment option for income investors alongside Johnson & Johnson (NYSE:JNJ), AbbVie Inc. (NYSE:ABBV), and Merck & Co., Inc. (NYSE:MRK).

At the end of March 2023, 73 hedge funds tracked by Insider Monkey owned stakes in Pfizer Inc. (NYSE:PFE), with a collective value of roughly $2.2 billion.

Diamond Hill Capital mentioned Pfizer Inc. (NYSE:PFE) in its Q3 2022 investor letter. Here is what the firm has to say:

“Also among our bottom contributors were health care products manufacturer Abbott Labs, global pharmaceutical company Pfizer Inc. (NYSE:PFE), media and technology giant Alphabet, and insurance company American International Group (AIG). Although Pfizer continues to report strong performance of its core drugs, sales of its COVID vaccine and treatment have likely peaked and sales are expected to decline going forward. We remain optimistic about the company long term as we believe management is taking the company in the right direction, focusing R&D, and making strategic acquisitions with profits generated from COVID vaccine sales.”

Click to continue reading and see 5 Best Healthcare Dividend Stocks to Buy.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…